Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
11(65%)
Results Posted
50%(1 trials)
Terminated
2(12%)

Phase Distribution

Ph early_phase_1
1
6%
Ph phase_1
8
47%
Ph phase_2
3
18%

Phase Distribution

9

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
8(66.7%)
Phase 2Efficacy & side effects
3(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

11

trials recruiting

Total Trials

17

all time

Status Distribution
Active(11)
Completed(2)
Terminated(3)
Other(1)

Detailed Status

Recruiting11
Completed2
Terminated2
Withdrawn1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
11
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (8.3%)
Phase 18 (66.7%)
Phase 23 (25.0%)

Trials by Status

withdrawn16%
suspended16%
completed212%
recruiting1165%
terminated212%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT05873699Phase 1

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

Recruiting
NCT04698564Phase 2

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Terminated
NCT05599048Phase 1

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

Recruiting
NCT02526368Early Phase 1

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

Recruiting
NCT05866679Phase 1

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Suspended
NCT05746208Phase 2

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Recruiting
NCT03067467

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

Recruiting
NCT03324360Phase 1

Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)

Recruiting
NCT06600906

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Recruiting
NCT04772456Phase 1

Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

Recruiting
NCT05697406Phase 1

HP Pyruvate MRI in Cancers

Recruiting
NCT06103201Phase 1

Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury

Recruiting
NCT03057002

UTSW HP [13-C] Pyruvate Injection in HCM

Completed
NCT04968210

Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)

Completed
NCT06645691Phase 2

Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body

Recruiting
NCT03129776Phase 1

Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer

Terminated
NCT03759704

Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)

Withdrawn

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17